$9.01
3.53% yesterday
Nasdaq, Nov 25, 10:16 pm CET
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Enanta Pharmaceuticals, Inc. Stock price

$9.01
-2.67 22.86% 1M
-3.02 25.10% 6M
-0.40 4.25% YTD
-0.57 5.95% 1Y
-77.88 89.63% 3Y
-53.68 85.63% 5Y
-36.34 80.13% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.33 3.53%
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Key metrics

Market capitalization $190.91m
Enterprise Value $186.39m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.59
P/S ratio (TTM) P/S ratio 2.65
P/B ratio (TTM) P/B ratio 1.28
Revenue growth (TTM) Revenue growth -10.71%
Revenue (TTM) Revenue $71.96m
EBIT (operating result TTM) EBIT $-122.87m
Free Cash Flow (TTM) Free Cash Flow $-100.33m
Cash position $230.69m
EPS (TTM) EPS $-5.46
P/E forward negative
Short interest 17.26%
Show more

Is Enanta Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Enanta Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

4x Buy
50%
3x Hold
38%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
38%
Sell
13%

Financial data from Enanta Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
72 72
11% 11%
100%
- Direct Costs 2.53 2.53
7% 7%
4%
69 69
11% 11%
96%
- Selling and Administrative Expenses 53 53
13% 13%
74%
- Research and Development Expense 137 137
16% 16%
190%
-120 -120
8% 8%
-167%
- Depreciation and Amortization 2.53 2.53
7% 7%
4%
EBIT (Operating Income) EBIT -123 -123
8% 8%
-171%
Net Profit -115 -115
13% 13%
-160%

In millions USD.

Don't miss a Thing! We will send you all news about Enanta Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enanta Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
about 16 hours ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2024. “Our fiscal fourth quarter was an exciting time for Enanta as we announced positive data from a P...
Neutral
Business Wire
2 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV.
Neutral
Business Wire
3 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Investor Conferences in September.
More Enanta Pharmaceuticals, Inc. News

Company Profile

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Luly
Employees 145
Founded 1995
Website www.enanta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today